Dhanvanthri Speciality Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-10-2024
- Paid Up Capital ₹ 5.00 M
as on 24-10-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.95 Cr
as on 24-10-2024
- Revenue 19.69%
(FY 2023)
- Profit 11.69%
(FY 2023)
- Ebitda 16.53%
(FY 2023)
- Net Worth 29.54%
(FY 2023)
- Total Assets 5.53%
(FY 2023)
About Dhanvanthri Speciality Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹8.95 Cr.
Bhavya Balaraj and Guttahalli Shridhar serve as directors at the Company.
- CIN/LLPIN
U24100KA2015PTC079594
- Company No.
079594
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dhanvanthri Speciality Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhavya Balaraj  | Director | 31-Mar-2015 | Current |
| Guttahalli Shridhar | Director | 31-Mar-2015 | Current |
Financial Performance and Corporate Structure Insights of Dhanvanthri Speciality Pharma.
Dhanvanthri Speciality Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.69% increase. The company also saw a substantial improvement in profitability, with a 11.69% increase in profit. The company's net worth Soared by an impressive increase of 29.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dhanvanthri Speciality Pharma?
In 2022, Dhanvanthri Speciality Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dhanvanthri Super Speciality Private LimitedActive 1 year 4 monthsBhavya Balaraj and Guttahalli Shridhar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 14 Feb 2023 | ₹4.10 Cr | Open |
Hdfc Bank Limited Creation Date: 31 Mar 2022 | ₹4.00 M | Open |
Others Creation Date: 01 Dec 2015 | ₹4.45 Cr | Open |
How Many Employees Work at Dhanvanthri Speciality Pharma?
Dhanvanthri Speciality Pharma has a workforce of 24 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dhanvanthri Speciality Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dhanvanthri Speciality Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
